ArticleJournal of clinical pathology2002
Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia.
Article in Journal of clinical pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 45 citations in OpenAlex.
- iWhale: a computational pipeline based on Docker and SCons for detection and annotation of somatic variants in cancer WES data.Briefings in bioinformatics · 2021Article
- Ectopic expression of p33Oncology letters · 2015Article
- A novel tumor suppressor gene in basal cell carcinoma: inhibition of growth factor-2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Src regulates the activity of the ING1 tumor suppressor.PloS one · 2013Article
- Cytoplasmic expression of p33(ING1b) is correlated with tumorigenesis and progression of human esophageal squamous cell carcinoma.Oncology letters · 2013Article
- The ING family tumor suppressors: from structure to function.Cellular and molecular life sciences : CMLS · 2011Review
- ING Genes Work as Tumor Suppressor Genes in the Carcinogenesis of Head and Neck Squamous Cell Carcinoma.Journal of oncology · 2011Article
- Inhibitor of growth tumor suppressors in cancer progression.Cellular and molecular life sciences : CMLS · 2010Review
- The ING gene family in the regulation of cell growth and tumorigenesis.Journal of cellular physiology · 2009Review
- Histone H3K4me3 binding is required for the DNA repair and apoptotic activities of ING1 tumor suppressor.Journal of molecular biology · 2008Article
- Nuclear to cytoplasmic shift of p33(ING1b) protein from normal oral mucosa to oral squamous cell carcinoma in relation to clinicopathological variables.Journal of cancer research and clinical oncology · 2008Article
- Nuclear ING2 expression is reduced in human cutaneous melanomas.British journal of cancer · 2006Article
- Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression.Molecular and cellular biology · 2006Article
- Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma.World journal of gastroenterology · 2005Article
- The role of the tumour suppressor p33 ING1b in human neoplasia.Journal of clinical pathology · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsp33(ING1b) is a tumour suppressor protein involved in growth control and apoptosis. Suppression of p33(ING1b) expression is associated with the loss of cellular growth control and immortalisation, whereas its overexpression causes cell cycle arrest. Moreover, normal p33(ING1b) expression is essential for optimal function of p53. Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood, accounting for one third of all childhood malignancies. A variety of cytogenetic abnormalities have been described but there is no single abnormality common to all cases. Deregulation of the TP53 pathway is a common genetic abnormality in human malignancies. However, TP53 mutations are uncommon in ALL. It is possible that alternative mechanisms of regulation of the TP53 apoptosis pathway, such as modulation of p33(ING1b) expression, may be important in ALL. The aim of this study was to assess the expression of p33(ING1b) in childhood ALL.
methodsOne hundred and forty five patients with childhood ALL were investigated in this immunohistochemical study of the expression of p33(ING1b).
resultsLoss of nuclear expression of p33(ING1b) was seen in 78% of cases. This was associated with increased cytoplasmic expression of the protein. Kaplan Meier survival analysis demonstrated a trend towards a better prognosis for patients with tumours that had lost nuclear p33(ING1b).
conclusionThese results suggest that the loss of nuclear p33(ING1b) expression may be an important molecular event in the pathogenesis of childhood ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.